Navigation Links
FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
Date:2/4/2011

t with a single fetus and had a history of a prior spontaneous preterm birth. Among women treated with Makena, 37 percent delivered early (before 37 weeks) as compared with 55 percent of women in the control group.  

A separate study evaluated the development of children born to mothers enrolled in the controlled trial. In this study, children ages 2.5 years to 5 years reached similar developmental targets, regardless of the mother's treatment.  The confirmatory study that is ongoing will be followed by a similar infant follow-up study, to be completed about 2018.  That study is expected to include 580-750 infants, depending on the number of study sites and mothers willing to participate.  

The most common side effects reported with Makena included pain, swelling, or itching at the injection site; hives, nausea and diarrhea. Serious adverse reactions were rare; there was a single report each of blood clot in the lungs (pulmonary embolism) and an infection at the injection site.

The FDA originally approved hydroxyprogesterone caproate under the trade name Delalutin in 1956 for use in pregnant women. The approved indications include threatened miscarriage. The original manufacturer requested the withdrawal of Delalutin from the market in 2000 for reasons unrelated to safety.

Consumers and health care professionals are encouraged to report adverse events from medications to the FDA's MedWatch program at 800-FDA-1088 or online at www.fda.gov/medwatch/how.htm.

Makena is manufactured by Baxter Pharmaceutical Solutions LLC, based in Bloomington, Ind.

For more information:

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/UCM054420  

<
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014  ResMed (NYSE: RMD ) ... Exchange program, a comprehensive suite of software and ... other health care providers. ResMed ... patient information. It integrates valuable sleep and respiratory ... management platforms with customers, in-house or third-party electronic ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho Oncology, ... Ltd. ( Japan ), announced that ... Fast Track designation for TAS-102 (nonproprietary names: trifluridine ... under investigation for the treatment of refractory metastatic ... initiated a rolling NDA submission to the FDA. ...
(Date:10/20/2014)... LONDON , October 20, 2014 ... study of its novel, low volume bowel preparation, NER1006, ... of the American College of Gastroenterology (ACG), ... end point of stool weight and co-primary endpoint of ... efficacy with NER1006 vs. MOVIPREP ® in screening ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... 7 MO BIO Laboratories, Inc., the ... announces the launch of a groundbreaking new product, LifeGuard ... samples upon collection. LifeGuard solution will enable researchers ... degradation or changes in transcript levels during transport to ...
... RIDGE, N.J., Oct. 7 With the growth in the ... WIRELESS I.T. & Entertainment 2009® that it is offering OnCare ... Manager application that helps address the specific needs of mobile ... efficient. , Designed specifically for use by home ...
Cached Medicine Technology:MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution 2Verizon Wireless Offers Home Health Care Industry Custom Mobile Application To Be More Productive 2
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
(Date:10/20/2014)... October 20, 2014 My Clients Plus ... software application. The new module enables easy administration ... full life-cycle quality care. , This application allows users ... their practice, attach a to-do item to a specific ... even set up reoccurring reminders for follow-ups. It's ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... October 20, 2014 It’s hard to imagine ... orphans and vulnerable children around the world, it’s a reality. ... people, many children are forced to walk barefoot on rocky ... families or play with their friends. , Buckner International's ... Air1 Radio in October to encourage support for ...
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
... District Health Boards (DHBs), striking junior doctors returned to hospital calling ... , ,The doctor's union - Resident Doctors' Association (RDA) and the ... Monday and planned to meet on Thursday for confirming the results. ... strike, which lasted for 5 days. , ,But unfortunately ...
... A new study conducted in Australia by the NSW Centre ... the eating habits of Australian children //. ,In ... show many kids quite frequently miss meals. The researchers interviewed ... what they ate and drank. ,They conducted this ...
... to a Danish study conducted by Dr. Morten Andersen of ... that doctors //who took part in pharmaceutical-sponsored clinical trials tend ... the Journal of the American Medical Association. The research team ... doctor knows the product well. It is also due to ...
... in hospitals against reservation policy there is yet another ... it is by the staff and the venue is ... is the incident wherein some RSS people unleashed violence ... steps to check overcrowding of the wards. ,The ...
... suffering, a tuberculosis (TB) patient in Madhya Pradesh has requested Indian ... life and that of his four minor children. ... late 40s, is suffering from TB and has long been dependent ... of TB a few years ago. ,He has now ...
... University study, members of rural Appalachian households who have minimal ... to become obese and develop diabetes. ,Researcher David ... 'food insecurity' had a greater body mass index (BMI) ... (an average BMI of 30.3 vs. average BMI of 29). ...
Cached Medicine News:Health News:Childhood Obesity Cause For Increasing Concerns 2Health News:Appalachians more prone to obesity and diabetes 2Health News:Appalachians more prone to obesity and diabetes 3
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: